The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with extranodal NK/T-cell lymphoma. The study sponsor is Cell Medica, and the principal investigator at Weill Cornell is Dr. Jia Ruan. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at email@example.com.
- Men and women age 18 and older
- Non-Hodgkin lymphoma called extranodal NK/T-cell lymphoma
- Disease has not gone away with treatment, or has come back
- Detailed eligibility reviewed when you contact the study team
The purpose of this study is to find out more about the safety and effects of giving CMD-003 (EBV T-cells, an investigational new product) to treat participants with extranodal natural killer T-cell lymphoma (NK/T-cell lymphoma).
In this study the investigational EBV specific T-cell product is grown from the participant’s own blood. Investigational means that it is being testing and has not been approved by Regulatory Agencies like the United States Food and Drug Administration (FDA).
There will be two phases in the study, the screening phase and the treatment phase. In the screening phase, the study doctor will need to take some of the participant’s blood and send it to a laboratory to manufacture the experimental autologous T-cell product. This manufacturing process will take about 35 days.
The treatment phase will consist of up to 5 CMD-003 T-cell doses given intravenously (into the veins) for about 10 minutes over 6 months. Participants will be seen by the study doctor at 8 regular study visits over a one year period. The study doctor will check how the cancer responds to the EBV T cell treatment with standard imaging. Some additional blood samples will be taken to check how the body is reacting to the drug.